The immunosuppressive mode of action of mizoribine. 1984

Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda

Mizoribine (MIZ) suppressed the mitogen response and mixed lymphocyte reaction (MLR) significantly at doses of 100 micrograms/ml and 10 micrograms/ml in a dose-response analysis. The 50% inhibition dose (ID50) was between 10 micrograms/ml and 1.0 microgram/ml, both in the mitogen response and MLR. In a kinetic study of the MLR, the degree of suppression with MIZ at a given dosage was essentially the same as the degree of suppression observed in the dose-response analysis when MIZ was added to MLR cultures from day 0 to day 4. In addition, MLR was more susceptible to the suppressive activity of MIZ at 100 micrograms/ml when MIZ was added near the peak of lymphocyte proliferation. This experiment also showed that MLR suppression induced by MIZ at 10 micrograms/ml was reversible and MLR activity had completely recovered 6-8 hr after its removal. MIZ had no inhibitory action on MLR-derived cytotoxic cells or the effector phase of cell mediated lymphocytotoxicity. These results clearly demonstrate that MIZ suppresses lymphoproliferation, but has no effect on the recognition phase or effector phase of cytotoxic lymphocytes.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008934 Mitogens Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) Mitogen,Phytomitogen,Phytomitogens
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012263 Ribonucleosides Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
February 1989, Transplantation proceedings,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
April 2002, Pediatrics international : official journal of the Japan Pediatric Society,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
January 1987, Japanese journal of ophthalmology,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
January 1975, Frontiers of biology,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
January 1986, Nihon Jinzo Gakkai shi,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
January 1971, Medicinski glasnik,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
March 1991, The Journal of clinical investigation,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
January 1969, Antibiotica et chemotherapia. Fortschritte. Advances. Progres,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
October 1974, Journal of the National Cancer Institute,
Y Ichikawa, and H Ihara, and S Takahara, and K Takada, and G R Shrestha, and M Ishibashi, and M Arima, and S Sagawa, and T Sonoda
August 1981, European journal of biochemistry,
Copied contents to your clipboard!